| ID |
原文 |
译文 |
| 977 |
危重型，符合以下情况之一者：出现呼吸衰竭且需要机械通气；或者出现休克；或者合并其他器官功能衰竭需ICU监护治疗。
|
Critical Cases
Meeting any of the following criteria: occurrence of Respiratory failure requiring mechanical ventilation; presence of shock; other organ failure that requires monitoring and treatment in the ICU.
|
| 978 |
针对危重型，我们根据氧合指数、呼吸系统顺应性等情况，进一步分为早期、中期、晚期。
|
Critical cases are further divided into early, middle and late stages according to the oxygenation index and compliance of Respiratory system.
|
| 979 |
●早期：100mmHg<氧合指数≤150mmHg，呼吸系统顺应性≥30mL/cmH2O，未合并肺以外脏器功能衰竭的，通过积极抗病毒、抗细胞因子风暴、对症支持处理，恢复机会较大。
|
● Early stage: 100 mmHg index ≤150 mmHg; compliance of Respiratory system ≥30 mL / cmH2O; without organ failure other than the lungs. The patient has a great chance of recovery through active antiviral, anti-cytokine storm, and supportive treatment.
|
| 980 |
●中期：指氧合指数60mmHg<氧合指数≤100mmHg，30mL/cmH2O>呼吸系统顺应性≥15mL/cmH2O，可同时合并其他脏器功能轻中度受损。
|
● Middle stage: 60 mmHg < oxygenation index ≤100 mmHg; 30 mL/cmH2O > compliance of Respiratory system ≥15 mL/cmH2O; may be complicated by other mild or moderate dysfunction of other organs.
|
| 981 |
●晚期：指氧合指数≤60mmHg，呼吸系统顺应性<15mL/cmH2O两肺弥漫性实变，需要人工膜肺支持，或出现其他重要脏器功能衰竭的，死亡风险显著提高。
|
● Late stage: oxygenation index ≤ 60 mmHg; compliance of Respiratory system <15 mL/cmH2O; diffuse consolidation of both lungs that requires the use of ECMO; or failure of other vital organs. The mortality risk is significantly increased.
|
| 982 |
六. 抗病毒治疗及时消除病原体 |
VI. Antiviral Treatment for Timely Elimination of Pathogens |
| 983 |
抗病毒治疗越早越好，可以减少重症、危重症的发生。 |
An early antiviral treatment can reduce the incidence of severe and critical cases. |
| 984 |
COVID-19虽然缺乏有明确临床证据的有效抗病毒药物，根据我国新冠病毒肺炎诊疗方案，结合冠状病毒结构特征，现阶段我们采取的抗病毒策略如下：
|
Although there is no clinical evidence for effective antiviral drugs, currently the antiviral strategies based on the characteristics of SAR-CoV-2 are adopted according to Protocols for Diagnosis and Treatment of COVID-19: Prevention, Control, Diagnosis and Management.
|
| 985 |
抗病毒方案
|
Antiviral Treatment
|
| 986 |
我们以洛匹那韦/利托那韦片2片po q12h联合阿比多尔片200mg po tid作为基础方案；使用该方案，49例患者出现第一次病毒核酸检测阴性平均时间为12d（95%可信
|
At FAHZU, lopinavir/ritonavir (2 capsules, po q12h) combined with arbidol (200 mg poq12h) were applied as the basic regimen. From the treatment experience of 49 patients in our hospital, the average time to achieve negative viral nucleic acid test for the first time was 12 days (95% CI: 8-15 days). |